Edgar Filing: GALAKATOS NICHOLAS

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

GALAKATOS NICHOLAS

2. Issuer Name and Ticker or Trading Symbol
PORTOLA PHARMACEUTICALS INC [PTLA]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET, 54TH FLOOR

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2013

(Street)

BOSTON, MA 02116

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/28/2013		C		39,344	A	⁽¹⁾ ⁽²⁾ ⁽³⁾ ⁽⁴⁾	39,344	I	MPM Asset Management Investors 2003 BVIII LLC ⁽⁵⁾
Common Stock	05/28/2013		C		171,747	A	⁽¹⁾ ⁽²⁾ ⁽³⁾ ⁽⁴⁾	171,747	I	MPM Bioventures III GmbH & Co. Beteiligungs KG ⁽⁵⁾
Common Stock	05/28/2013		C		61,373	A	⁽¹⁾ ⁽²⁾ ⁽³⁾ ⁽⁴⁾	61,373	I	MPM BioVentures III Parallel Fund, L.P. ⁽⁵⁾
Common Stock	05/28/2013		C		136,641	A	⁽¹⁾ ⁽²⁾ ⁽³⁾ ⁽⁴⁾	136,641	I	MPM BioVentures III, L.P. ⁽⁵⁾
Common Stock	05/28/2013		C		2,032,239	A	⁽¹⁾ ⁽²⁾ ⁽³⁾ ⁽⁴⁾	2,032,239	I	MPM BioVentures III-QP, L.P. ⁽⁵⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series A Preferred Stock

⁽¹⁾

05/28/2013

15,642

⁽¹⁾

⁽⁶⁾

Common Stock

15,642

$ 0

MPM Asset Management Investors 2003 BVIII LLC ⁽⁵⁾

Series A Preferred Stock

⁽¹⁾

05/28/2013

68,280

⁽¹⁾

⁽⁶⁾

Common Stock

68,280

$ 0

MPM Bioventures III GmbH & Co. Beteiligungs KG ⁽⁵⁾

Series A Preferred Stock

⁽¹⁾

05/28/2013

24,400

⁽¹⁾

⁽⁶⁾

Common Stock

24,400

$ 0

MPM BioVentures III Parallel Fund, L.P. ⁽⁵⁾

Series A Preferred Stock

⁽¹⁾

05/28/2013

54,323

⁽¹⁾

⁽⁶⁾

Common Stock

54,323

$ 0

MPM BioVentures III, L.P. ⁽⁵⁾

Series A Preferred Stock

⁽¹⁾

05/28/2013

807,939

⁽¹⁾

⁽⁶⁾

Common Stock

807,939

$ 0

MPM BioVentures III-QP, L.P. ⁽⁵⁾

Series B Preferred Stock

⁽²⁾

05/28/2013

10,710

⁽²⁾

⁽⁶⁾

Common Stock

10,710

$ 0

MPM Asset Management Investors 2003 BVIII LLC ⁽⁵⁾

Series B Preferred Stock

⁽²⁾

05/28/2013

46,752

⁽²⁾

⁽⁶⁾

Common Stock

46,752

$ 0

MPM Bioventures III GmbH & Co. Beteiligungs KG ⁽⁵⁾

Series B Preferred Stock

⁽²⁾

05/28/2013

16,707

⁽²⁾

⁽⁶⁾

Common Stock

16,707

$ 0

MPM BioVentures III Parallel Fund, L.P. ⁽⁵⁾

Series B Preferred Stock

⁽²⁾

05/28/2013

37,196

⁽²⁾

⁽⁶⁾

Common Stock

37,196

$ 0

MPM BioVentures III, L.P. ⁽⁵⁾

Series B Preferred Stock

⁽²⁾

05/28/2013

553,204

⁽²⁾

⁽⁶⁾

Common Stock

553,204

$ 0

MPM BioVentures III-QP, L.P. ⁽⁵⁾

Series C Preferred Stock

⁽³⁾

05/28/2013

10,658

⁽³⁾

⁽⁶⁾

Common Stock

10,658

$ 0

MPM Asset Management Investors 2003 BVIII LLC ⁽⁵⁾

Series C Preferred Stock

⁽³⁾

05/28/2013

46,526

⁽³⁾

⁽⁶⁾

Common Stock

46,526

$ 0

MPM Bioventures III GmbH & Co. Beteiligungs KG ⁽⁵⁾

Series C Preferred Stock

⁽³⁾

05/28/2013

16,625

⁽³⁾

⁽⁶⁾

Common Stock

16,625

$ 0

MPM BioVentures III Parallel Fund, L.P. ⁽⁵⁾

Series C Preferred Stock

⁽³⁾

05/28/2013

37,016

⁽³⁾

⁽⁶⁾

Common Stock

37,016

$ 0

MPM BioVentures III, L.P. ⁽⁵⁾

Series C Preferred Stock

⁽³⁾

05/28/2013

550,530

⁽³⁾

⁽⁶⁾

Common Stock

550,530

$ 0

MPM BioVentures III-QP, L.P. ⁽⁵⁾

Series D Preferred Stock

⁽⁴⁾

05/28/2013

2,334

⁽⁴⁾

⁽⁶⁾

Common Stock

2,334

$ 0

MPM Asset Management Investors 2003 BVIII LLC ⁽⁵⁾

Series D Preferred Stock

⁽⁴⁾

05/28/2013

10,189

⁽⁴⁾

⁽⁶⁾

Common Stock

10,189

$ 0

MPM Bioventures III GmbH & Co. Beteiligungs KG ⁽⁵⁾

Series D Preferred Stock

⁽⁴⁾

05/28/2013

3,641

⁽⁴⁾

⁽⁶⁾

Common Stock

3,641

$ 0

MPM BioVentures III Parallel Fund, L.P. ⁽⁵⁾

Series D Preferred Stock

⁽⁴⁾

05/28/2013

8,106

⁽⁴⁾

⁽⁶⁾

Common Stock

8,106

$ 0

MPM BioVentures III, L.P. ⁽⁵⁾

Series D Preferred Stock

⁽⁴⁾

05/28/2013

120,566

⁽⁴⁾

⁽⁶⁾

Common Stock

120,566

$ 0

MPM BioVentures III-QP, L.P. ⁽⁵⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
GALAKATOS NICHOLAS C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116	X

Signatures

/s/ Sally A. Kay, as attorney-in-fact		05/28/2013
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
(2)	Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
(3)	Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
(4)	Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
(5)	MPM BioVentures III GP, L.P. and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Dr. Galakatos is a Series A member of MPM BioVentures III LLC and Manager of MPM Asset Management Investors 2003 BVIII LLC and shares voting and dispositive power over the shares held by MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM BioVentures III Parallel Fund, L.P. and MPM Asset Management Investors 2003 BVIII LLC. Dr. Galakatos disclaims beneficial ownership of the shares identified in this footnote except to the extent of his respective proportionate pecuniary interest in such shares.
(6)	The shares do not have an expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.